A 65-year-old male is discharged after an acute ischemic stroke. His workup reveals no evidence of cardioembolic source or large vessel stenosis, suggesting a lacunar stroke. He has a history of hypertension and hyperlipidemia. What is the most appropriate long-term antiplatelet therapy for secondary stroke prevention?
✓ Correct Answer: Option B
For patients with non-cardioembolic ischemic stroke, antiplatelet therapy is crucial for secondary prevention. Aspirin 81 mg daily is a standard first-line agent, unless contraindicated. Oral anticoagulants like warfarin or rivaroxaban are for cardioembolic causes.